Navigation Links
Vermillion Reports Third Quarter 2013 Results
Date:11/14/2013

ion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Forward-Looking Statement
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding Vermillion's expected cash outlay and Vermillion's ability to regain traction in reimbursement. Words such as "may," "expects," "intends," "anticipates," "believes," "estimates," "plans," "seeks," "could," "should," "continue," "will," "potential," "projects" and similar expressions are intended to identify forward-looking statements.  The forward-looking statements contained in this press release are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
3. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
4. Vermillion Appoints Dr. Eric Varma to its Board of Directors
5. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
6. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
7. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
8. Vermillion Reports Fourth Quarter and Full Year 2012 Results
9. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
10. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
11. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Shire ... today that it has acquired New ... for $300 million. With the acquisition, Shire acquires ... combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), ... of infectious conjunctivitis, an ocular surface condition commonly ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, ... the pivotal TELESTAR Phase 3 clinical trial met ... telotristat etiprate in treating cancer patients with carcinoid ... current standard of care. Telotristat etiprate was discovered ... technology, and is the company,s first discovery to ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Medical AB ( http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, OTC: ... B)(OTC: DMYDY)announced today that the Swedish Medical Products,Agency (MPA) has ... therapeutic diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ...
... Onset with SYMBICORT with Improved Lung Function within ... ... WILMINGTON, Del., March 18 Data from a new,study demonstrated ... greater,and faster bronchodilatory effects, or opening of the airways, compared,with ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 3Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 4
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number ... according to market research compiled for the National Association of Dental Laboratories ( ... Labor, Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists ...
(Date:8/3/2015)... ... 2015 , ... Constantin Vasilica, 48 from Romania wanted to have an alternative ... many years of suffering and using medications with strong side effects. This had already ... extra time off or wait longer hours in the waiting rooms. Instead, he went ...
(Date:8/3/2015)... ... 03, 2015 , ... The American Institute of Architects ... to collaborate across a wide range of initiatives ranging from code development and ... , “Our combined membership, consisting of practicing design professionals, code officials, and the ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
Breaking Medicine News(10 mins):Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2
... Exposition Park LOS ANGELES, ... March of Dimes premier fundraising event that benefits all babies--those ... thrive. 11,000 walkers are expected at this largest March for ... Exposition Park, at the corner of S. Figueroa and 39th ...
... associations representing the state,s 114 hospitals have reached a ... 2010.Among other principles, the groups urged the state to ... agreed on a minimum floor that all hospitals should ... shared today with members of the state Legislature by ...
... Saturday, April 25 from 9 a.m. until noon, ... (NAMI-OC) will bring together speakers, agencies and service ... Front Line conferences provide important information on PTSD ... and suicide prevention. The conference is designed not ...
... The National Medical Association (NMA), the nation,s premier ... funding in the amount of $120,000 from the ... of a three-year grant commitment, designed "to promote ... sustaining collaboration among partner organizations."Partner organizations for this ...
... favors people in urban areas , , TUESDAY, April 21 (HealthDay ... or remote areas are not less likely to get a ... finds. , Researchers analyzed U.S. data on 699,751 adults ... list between 1995 and 2007. After about two years on ...
... Patients who drank before diagnosis had reduced risk of ... (HealthDay News) -- Patients with non-Hodgkin lymphoma who drank ... risk of relapse or death, according to a study ... researchers looked at more than 500 women with non-Hodgkin ...
Cached Medicine News:Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Hospital Groups Stand United on State Budget 2Health News:Hospital Groups Stand United on State Budget 3Health News:Hospital Groups Stand United on State Budget 4Health News:National Medical Association Receives Funding From Kellogg for Training Community Advocates 2Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Wine May Guard Against Lymphoma Recurrence 2
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
Pre-Saturated Sponge Sticks...
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
Medicine Products: